Development and initial psychometric properties of the Cannabidiol Outcome Expectancies Questionnaire (CBD-OEQ).
Development and initial psychometric properties of the Cannabidiol Outcome Expectancies Questionnaire (CBD-OEQ).
复制标题
DOI：
10.1037/pas0001128
复制
发表时间：
2022-07
影响因子：
3.6
通讯作者：
Buckner, Julia D
中科院分区：
文献类型：
--
作者：
Walukevich-Dienst, Katherine;Morris, Paige E;Tucker, Raymond P;Copeland, Amy L;Buckner, Julia D
大麻二酚 (CBD) 是一种非精神活性大麻素，被许多人用来治疗医疗和心理健康状况，尽管对 CBD 对这些疾病的功效的支持有限。确定 CBD 相关的结果预期（即关于 CBD 预期效果的信念）可能有助于了解 CBD 使用的病因和维持和/或有助于管理或临床试验研究。尽管大麻预期结果有多种衡量标准，但大麻包含多种活性化合物（例如四氢大麻酚 [THC]、CBD）。因此，大麻结果预期可能无法反映 CBD 特定的结果预期。然而，尚不存在已知的针对 CBD 的具体结果预期指标。本研究采用三阶段混合方法来开发和测试大麻二酚结果预期问卷（CBD-OEQ）的心理测量特性。 CBD-OEQ 评估了认可度（即个人对预期结果的同意/不同意程度）和合意性评级（即预期结果的合意程度）。最初的项目池对象是 600 名认可听说过或使用 CBD 产品的成年人。因子分析支持 60 项、六因子结构。本样本中 CBD-OEQ 分量表分数的内部一致性以及收敛性、判别性和增量有效性得到了初步支持。期望评级解释了大多数子量表 CBD 变量的最小附加方差，但调节了全球负面影响和无影响子量表的认可评级和使用行为之间的关系。新开发的 CBD-OEQ 既可用作研究工具，也可用作临床工具。
Cannabidiol (CBD), a nonpsychoactive cannabinoid, is used by many individuals to treat medical and mental health conditions, despite limited support for the efficacy of CBD for these conditions. Identification of CBD-related outcome expectancies (i.e., beliefs concerning the anticipated effects of CBD) could be useful in understanding the etiology and maintenance of CBD use and/or be useful in administration or clinical trial research. Although there are several measures of cannabis outcome expectancies, cannabis comprises several active compounds (e.g., tetrahydrocannabinol [THC], CBD). Thus, cannabis outcome expectancies may not reflect CBD-specific outcome expectancies. Yet, no known CBD-specific outcome expectancy measure exists. The present study used a three-phase, mixed-methods approach to develop and test the psychometric properties of the Cannabidiol Outcome Expectancy Questionnaire (CBD-OEQ). The CBD-OEQ assessed endorsement (i.e., how much an individual agrees/disagrees with an expected outcome) and desirability ratings (i.e., how desirable an expected outcome is). The initial item pool was administered to 600 adults who endorsed having heard of or using CBD products. Factor analyses supported a 60-item, six-factor structure. There was an initial support for internal consistency and convergent, discriminant, and incremental validity of the CBD-OEQ subscale scores in the present sample. Desirability ratings explained minimal additional variance in CBD variables for most subscales, but moderated the relationship between endorsement ratings and use behaviors for Global Negative Effects and No Effect subscales. The newly developed CBD-OEQ could be used as both a research and a clinical tool.